The most potent partners for CDK inhibitors in multiple myeloma are the HDAC inhibitors CUDC101 and CUDC907, the MEK1/2 inhibitor trametinib, the NOTCH inhibitor PF-03084014, the BCL2 inhibitors GX15-070 and ABT-263, the IDH1/2 inhibitor AGI-5180, the FLT3 and JAK2 inhibitor SB1317 and also the FGFR-targeting inhibitors XL999 and nintedanib. This evidence concerns the gene JAK2 and AL amyloidosis.